Research and Markets: Global Ophthalmology Drug Pipeline Capsule - 2012

Research and Markets: Global Ophthalmology Drug Pipeline Capsule - 2012

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Fore Pharma's latest report Global Ophthalmology Drug Pipeline Capsule - 2012' provides up-to-date information on key research and development activities in the global ophthalmology drug market. It covers active pipeline molecules under development in various stages of clinical trials, preclinical research, and drug discovery for Age-related Macular Degeneration, Allergic Conjunctivitis, Diabetic Macular, Diabetic Retinopathy, Glaucoma, and Uveitis.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating business opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company, mechanism of action, stage (phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and drug discovery), and geography (North America, Europe, and Asia).

- Ophthalmology Drug Pipeline Insights

- Age-related Macular Degeneration Drug Pipeline Insights

- Allergic Conjunctivitis Drug Pipeline Insights

- Diabetic Macular Edema Drug Pipeline Insights

- Diabetic Retinopathy Drug Pipeline Insights

- Glaucoma Drug Pipeline Insights

- Uveitis Drug Pipeline Insights

- Tables and Figures included

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.